These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 10574413)

  • 1. Long-term safety and antihypertensive efficacy of irbesartan: pooled results of five open-label studies.
    Littlejohn T; Saini R; Kassler-Taub K; Chrysant SG; Marbury T
    Clin Exp Hypertens; 1999 Nov; 21(8):1273-95. PubMed ID: 10574413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The long-term antihypertensive activity and tolerability of irbesartan with hydrochlorothiazide.
    Raskin P; Guthrie R; Flack J; Reeves R; Saini R
    J Hum Hypertens; 1999 Oct; 13(10):683-7. PubMed ID: 10516738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The antihypertensive efficacy of the combination of irbesartan and hydrochlorothiazide assessed by 24-hour ambulatory blood pressure monitoring. Irbesartan Multicenter Study Group.
    Howe P; Phillips P; Saini R; Kassler-Taub K
    Clin Exp Hypertens; 1999 Nov; 21(8):1373-96. PubMed ID: 10574419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension.
    Kochar M; Guthrie R; Triscari J; Kassler-Taub K; Reeves RA
    Am J Hypertens; 1999 Aug; 12(8 Pt 1):797-805. PubMed ID: 10480473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial combination therapy with irbesartan/hydrochlorothiazide for hypertension: an analysis of the relationship between baseline blood pressure and the need for combination therapy.
    Franklin S; Lapuerta P; Cox D; Donovan M
    J Clin Hypertens (Greenwich); 2007 Dec; 9(12 Suppl 5):15-22. PubMed ID: 18046108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Irbesartan/Losartan Study Investigators.
    Oparil S; Guthrie R; Lewin AJ; Marbury T; Reilly K; Triscari J; Witcher JA
    Clin Ther; 1998; 20(3):398-409. PubMed ID: 9663357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the efficacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension.
    Neutel JM; Franklin SS; Lapuerta P; Bhaumik A; Ptaszynska A
    J Hum Hypertens; 2008 Apr; 22(4):266-74. PubMed ID: 17928878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension.
    Pool JL; Guthrie RM; Littlejohn TW; Raskin P; Shephard AM; Weber MA; Weir MR; Wilson TW; Wright J; Kassler-Taub KB; Reeves RA
    Am J Hypertens; 1998 Apr; 11(4 Pt 1):462-70. PubMed ID: 9607385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of irbesartan added to hydrochlorothiazide for the treatment of hypertension in patients non-responsive to hydrochlorothiazide alone.
    Rosenstock J; Rossi L; Lin CS; MacNeil D; Osbakken M
    J Clin Pharm Ther; 1998 Dec; 23(6):433-40. PubMed ID: 10048504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, as assessed by ambulatory blood pressure monitoring: the MAPAVEL Study (Monitorización Ambulatoria Presión Arterial APROVEL).
    Coca A; Calvo C; García-Puig J; Gil-Extremera B; Aguilera MT; de la Sierra A; Martín-Hidalgo A; Marín R;
    Clin Ther; 2002 Jan; 24(1):126-38. PubMed ID: 11833827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and tolerability of fixed-dose irbesartan/hydrochlorothiazide for rapid control of severe hypertension.
    Neutel JM; Franklin SS; Bhaumik A; Lapuerta P; Oparil S
    Clin Exp Hypertens; 2009 Oct; 31(7):572-84. PubMed ID: 19886855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension.
    Weir MR; Elkins M; Liss C; Vrecenak AJ; Barr E; Edelman JM
    Clin Ther; 1996; 18(3):411-28. PubMed ID: 8829017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irbesartan/hydrochlorothiazide for the treatment of isolated systolic hypertension: a subgroup analysis of the INCLUSIVE trial.
    Chrysant SG; Neutel JM; Ferdinand KC;
    J Natl Med Assoc; 2009 Apr; 101(4):300-7. PubMed ID: 19397219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. I-ADD study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with irbesartan monotherapy in hypertensive patients uncontrolled with irbesartan 150 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study.
    Bobrie G;
    Clin Ther; 2012 Aug; 34(8):1720-34.e3. PubMed ID: 22853847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the angiotensin II receptor antagonist irbesartan with atenolol for treatment of hypertension.
    Stumpe KO; Haworth D; Hoglund C; Kerwin L; Martin A; Simon T; Masson C; Kassler-Taub K; Osbakken M
    Blood Press; 1998 Jan; 7(1):31-7. PubMed ID: 9551875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.
    O'Brien E; Barton J; Nussberger J; Mulcahy D; Jensen C; Dicker P; Stanton A
    Hypertension; 2007 Feb; 49(2):276-84. PubMed ID: 17159081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide.
    Chrysant SG; Weber MA; Wang AC; Hinman DJ
    Am J Hypertens; 2004 Mar; 17(3):252-9. PubMed ID: 15001200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of irbesartan vs felodipine in the regression after 1 year of left ventricular hypertrophy in hypertensive patients (the SILVER trial). Study of Irbesartan in Left VEntricular hypertrophy Regression.
    Cohen A; Bregman B; Agabiti Rosei E; Williams B; Dubourg O; Clairefond P; Brudi P; Gosse P; Guéret P
    J Hum Hypertens; 1998 Jul; 12(7):479-83. PubMed ID: 9702935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of the efficacy and safety of irbesartan/hydrochlorothiazide combination therapy with irbesartan monotherapy in the treatment of moderate or severe hypertension in diabetic and obese hypertensive patients: a post-hoc analysis review.
    Neutel JM
    Postgrad Med; 2011 Jul; 123(4):126-34. PubMed ID: 21680997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of monotherapy with irbesartan 150 mg or amlodipine 5 mg for treatment of mild-to-moderate hypertension.
    Neutel JM; Germino FW; Smith D
    J Renin Angiotensin Aldosterone Syst; 2005 Sep; 6(2):84-9. PubMed ID: 16470487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.